Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)

Advice

NICE is unable to make a recommendation about the use in the NHS of regorafenib for metastatic colorectal cancer after treatment for metastatic disease because no evidence submission was received from Bayer for the technology.